Ganitumab

Summary

Ganitumab (CHEMBL1743024) is a phase-3 clinical-stage antibody; indicated across 12 conditions including ovarian neoplasm and ewing sarcoma; with CIViC clinical evidence for 2 variant-indication associations (e.g. IGF2 Overexpression in pancreatic adenocarcinoma).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 12 conditions
• Clinical trials: 12
• Precision-oncology evidence (CIViC): 2 variant–indication associations

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743024
Name	Ganitumab
Type	Antibody
Max phase	3

Also known as: AMG 479, AMG-479, AMG479, Ganitumab, GANITUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
ovarian neoplasm	2	MONDO:0021068	EFO:0003893
Ewing sarcoma	2	MONDO:0012817	EFO:0000174
angiosarcoma	2	MONDO:0016982	EFO:0003968
breast neoplasm	2	MONDO:0021100	MONDO:0007254
neoplasm	1	MONDO:0005070	EFO:0000616
small cell lung carcinoma	1	MONDO:0008433	EFO:0000702
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
rhabdomyosarcoma	1	MONDO:0005212	EFO:0002918
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE1/PHASE2	3
PHASE2	3
PHASE1	3
Not specified	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02306161	PHASE3	ACTIVE_NOT_RECRUITING	Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT00788957	PHASE1/PHASE2	COMPLETED	Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NCT00891930	PHASE2	COMPLETED	Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NCT01327612	PHASE2	COMPLETED	Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
NCT01473303	PHASE1/PHASE2	WITHDRAWN	Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
NCT03041701	PHASE1/PHASE2	TERMINATED	Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
NCT04129151	PHASE2	TERMINATED	Palbociclib + Ganitumab In Ewing Sarcoma
NCT00562380	PHASE1	COMPLETED	AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
NCT01122199	PHASE1	COMPLETED	Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
NCT01298401	PHASE1	COMPLETED	Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
NCT04199026	Not specified	RECRUITING	Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
NCT03029481	Not specified	NO_LONGER_AVAILABLE	Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

Clinical evidence (CIViC)

Variant × indication × effect (2 predictive associations from 2 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
IGF2 Overexpression	Pancreatic Adenocarcinoma	Sensitivity/Response	Ganitumab + Gemcitabine	CIViC B	EID7000
IGF2 Overexpression	Ovarian Cancer	Sensitivity/Response	Ganitumab	CIViC D	EID6972

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).